Successful Treatment of Macular Retinoblastoma With Superselective Ophthalmic Artery Infusion of Melphalan

Abstract

SOAIM can be of value in the treatment of macular retinoblastoma. It may allow the salvage of the residual eyesight with a low rate of complications due to the local and systemic toxicity related to chemotherapy.

Targeted retinoblastoma management

“…In a 4-year perspective, Gobin et al [46] found that IAC was well tolerated and effective for retinoblastoma with globe salvage at 2 years in 82% if IAC was primary treatment and 58% if secondary treatment. Shields et al [47] [49] showed excellent control of macular retinoblastoma. Thampi et al [50] noted 86% response rate in groups A, B, and C but only 38% response in groups D and E. In a small cohort of 18 eyes, Schaiquevich et al [51] found that IAC was more effective than POC or IVC for treatment of relapsed retinoblastoma.…”

Recent Advances in Retinoblastoma Treatment

“…No animal or human studies were carried out by the author for this article. Since our fi rst report multiple groups worldwide have adopted and then published on IAC (Muen et al 2012 ;Shields et al 2014 ;Peterson et al 2011 ;Thampi et al 2013 ;Grigorovski et al 2014 ;Hadjistilianou et al 2014 ;Jabbour et al 2012 ). The idea was forgotten for almost 30 years, until in 1993 Mohri et al, from the Tokyo University and the Japan National Cancer Center, started routinely using IAC.…”

"Unifocality as Prognostic Factor for Unilateral Retinoblastoma: Preliminary Results of 32 Eyes Treated with Intra-Arterial Chemotherapy Alone"

“…New therapeutic paradigms significantly improved the chances of anatomical and, often, functional preservation of the globe even with advanced stage diseases [7][8][9]. The introduction of selective for eyes with subretinal and vitreous seeding, with the majority of patients receiving 3 or less cycles of IAC with one to three drugs [11].…”